CTEP
From Wikipedia, the free encyclopedia
 |
|
| Identifiers | |
|---|---|
|
|
| PubChem (CID) | 11646823 |
| IUPHAR/BPS | 6409 |
| ChemSpider | 9821562 |
| Chemical and physical data | |
| Formula | C19H13ClF3N3O |
| Molar mass | 391.774 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
CTEP is a research drug developed by Hoffmann-La Roche that acts as a selective allosteric antagonist of the metabotropic glutamate receptor subtype mGluR5, binding with nanomolar affinity and over 1000 times selectivity over all other receptor targets tested. In animal studies it was found to have a high oral bioavailability and a long duration of action, lasting 18 hours after a single dose, giving it considerably improved properties over older mGluR5 antagonists such as MPEP and fenobam.[1]
References[edit]
- ^ Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. Journal of Pharmacology and Experimental Therapeutics. 2011 Nov;339(2):474-86. PMID 21849627
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
